Analytical Data
-
基因名
LILRA5/CD85f
- Application
-
别名
CD85 antigen-like family member F Immunoglobulin-like transcript 11 Short name: ILT-11 Leukocyte immunoglobulin-like receptor 9 Short name: LIR-9 CD_antigen: CD85f
-
种属
Human
-
表达系统
HEK293
-
标签
N- His-Myc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
A6NI73
-
表达区间
42-268aa
-
分子量
29.2 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Related Products
Protein Description
LILRA5, also known as CD85f, is a member of the leukocyte immunoglobulin-like receptor (LILR) family, which is important for regulating immune responses. This receptor is predominantly expressed on immune cells such as monocytes, dendritic cells, and macrophages, and plays a crucial role in recognizing various ligands, including major histocompatibility complex (MHC) molecules and other immune regulatory proteins. Due to its inhibitory functions, LILRA5/CD85f is thought to be involved in modulating inflammation and preventing excessive immune activation, making it a significant target for understanding autoimmune diseases and other inflammatory conditions.
Recent studies have focused on the recombinant expression of LILRA5/CD85f to investigate its structural properties, ligand interactions, and functional roles in immune regulation. By producing this recombinant protein, researchers aim to elucidate the signaling pathways activated by LILRA5/CD85f and its potential implications in therapeutic strategies for diseases characterized by dysregulated immune responses. Understanding this receptor’s biological mechanisms may pave the way for novel immunotherapies, highlighting the necessity of further exploring the complexities of immune checkpoints and receptor-ligand interactions in the context of disease.
